Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2006

View Archived Issues

MPC-7869 studied for drug interaction potential, efficacy in Alzheimer's disease

MK-677 does not affect Alzheimer's disease progression

Sipuleucel-T improves survival in hormone refractory prostate cancer

Acenta and PsychoGenics form psychiatric and neurological disorders collaboration

Alnylam and Inex advance collaboration on systemic delivery of RNAi therapeutics

Alnylam and UT Southwestern to develop RNAi therapeutics for high cholesterol

Transition Therapeutics and Novo Nordisk amend I.N.T. license agreement

Rivastigmine transdermal patch compares well with capsules

Tigris licenses anticancer compound from NIH

Astellas discontinues development of FK-962 for Alzheimer's disease

Cangene's NDA for rhGH Accretropin accepted for review

AstraZeneca files NDA for Seroquel SR

Topical antiinfective REP-8839 begins phase I testing

Starpharma cleared to study SPL-7013 gel for genital herpes prevention

Roche exercises option to Ipsen's antidiabetic drug BIM-51077

U.K. clearance for phase II study of Reolysin with low-dose radiation

Expanded multiple dose phase I trial of CG-0070 in recurrent bladder cancer

Theravance and Astellas add Japan to telavancin collaboration

Mycophenolate mofetil approved in Malaysia for lupus nephritis

Solvay seeks E.U. approval of Synordia

Frova filed for prevention of menstrual migraine

Calpain inhibitor and antioxidant BN-82270 protects from and helps recover hearing loss

First U.S. clinical data on huperzine A, a Chinese herbal medicine for AD

Promising preclinical data on novel classes of compounds developed at Enkam

Recent patents disclose novel antiinfective agents

Recent ViroChem patent reports novel HIV integrase inhibitors

Recent Novartis and Devgen patents describe new treatments for cardiovascular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...